Karl Anderson, MD

Disc Medicine Inc

10/27/22 → 10/26/27

Project: Other project

Safety and Efficacy of Panhematin for Prevention of Acute Attacks of Porphyria

12/13/21 → 12/12/23

Project: Other project

A Phase 3, Multicenter, Open-Label, Long-Term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

10/25/21 → 10/24/26

Project: Other project

A Phase 3, Multicenter, Open-Label, Long-Term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

10/25/21 → 10/24/26

Project: Other project

Alnylam Pharmaceuticals, Inc. - 0306060, Assessing Patients' Experiences With Acute Hepatic Porphyria: Exit Interviews (Pro00053618)

10/6/21 → 10/5/24

Project: Other project

Alnylam Pharmaceuticals, Inc. - 0306060, Assessing Patients' Experiences With Acute Hepatic Porphyria: Exit Interviews (Pro00053618)

10/6/21 → 10/5/24

Project: Other project

Effect of Oral Cimetidine in the Protoporphyrias (IND 152831 submitted 9/2/2020)

MASSACHUSETTS GENERAL HOSPITAL

9/10/21 → 4/30/24

Project: Other project

ELEVATE, a global observational longitudinal prospective registry of patients with acute hepatic porphyria (AHP)

8/20/21 → 8/19/26

Project: Other project

ELEVATE, a global observational longitudinal prospective registry of patients with acute hepatic porphyria (AHP)

8/20/21 → 8/19/26

Project: Other project

RE- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria

5/15/21 → 9/16/25

Project: Other project

RE- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria

5/15/21 → 9/16/25

Project: Other project

RE: Porphyria Rare Disease Clinical Research Consortium (RDCRC)

5/14/21 → 6/30/24

Project: Other project

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria

9/17/20 → 9/16/25

Project: Other project

A Natural History Study of Acute Hepatic Porphyria (AHP) Patients with Recurrent Attacks ALN-AS1-NT-001

8/14/14 → 12/31/23

Project: Other project

Completed

The ABCG2 transporter in protoporphyrin IX disposition: from toxicity to therapy

University of Pittsburgh

7/1/21 → 4/30/22

Project: Other project

RE: A Natural History Study of Acute Hepatic Porphyria (AHP) Patients with Recurrent Attacks ALN-AS1-NT-001

5/15/21 → 5/15/21

Project: Other project

Newer Direct-Acting Anti-Viral

5/15/21 → 4/30/22

Project: Other project

RE: Porphyria Rare Disease Clinical Research Consortium (RDCRC)

5/14/21 → 6/30/23

Project: Other project

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria

9/17/20 → 5/14/21

Project: Other project

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria

9/17/20 → 5/14/21

Project: Other project

Porphyria Rare Disease Clinical Research Consortium (RDCRC)

9/18/19 → 5/14/21

Project: Other project

Porphyria Rare Disease Clinical Research Consortium (RDCRC)

Icahn School of Medicine at Mount Sinai

9/18/19 → 6/30/21

Project: Other project

Porphyria Rare Disease Clinical Research Consortium (RDCRC)

Icahn School of Medicine at Mount Sinai

9/18/19 → 5/14/21

Project: Other project

Task Order 1

Aptinyx Inc

7/17/18 → 12/31/19

Project: Other project

Testing Services

7/17/18 → 12/31/19

Project: Other project

Task Order 1

7/17/18 → 12/31/19

Project: Other project

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria

6/6/18 → 6/5/23

Project: Other project

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria

6/6/18 → 11/30/20

Project: Other project

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria

6/6/18 → 11/30/20

Project: Other project

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias

3/8/18 → 3/31/21

Project: Other project

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias

3/8/18 → 3/31/21

Project: Other project

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias

3/8/18 → 9/4/21

Project: Other project

Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects with Chronic Hepatitis C

6/22/17 → 4/30/22

Project: Other project

Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects with Chronic Hepatitis C

6/22/17 → 5/14/21

Project: Other project

Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects with Chronic Hepatitis C

Wake Forest University

6/22/17 → 5/14/21

Project: Other project

A Multicenter, Open-label Extension Study to Evaluate the long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a previous Clinical Study with ALS-AS1

12/28/16 → 4/30/21

Project: Other project

A Multicenter, Open-label Extension Study to Evaluate the long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a previous Clinical Study with ALS-AS1

12/28/16 → 4/30/21

Project: Other project

A Multicenter, Open-label Extension Study to Evaluate the long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a previous Clinical Study with ALS-AS1

12/28/16 → 4/30/21

Project: Other project

RE:A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria

11/12/16 → 8/31/21

Project: Other project

RE:A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria

11/12/16 → 8/31/21

Project: Other project

A PHASE 1, SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE, AND MULTI DOSE SAFETY, TOLERABILITY, PHARAMCOKINETICS, AND PHARACODYNAMICS STUDY OF SUBCUTANEOUSLY ADMINISTERED ALN-AS1 IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP)

1/22/16 → 1/21/19

Project: Other project

A PHASE 1, SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE, AND MULTI DOSE SAFETY, TOLERABILITY, PHARAMCOKINETICS, AND PHARACODYNAMICS STUDY OF SUBCUTANEOUSLY ADMINISTERED ALN-AS1 IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP)

1/22/16 → 1/21/19

Project: Other project

A PHASE 1, SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE, AND MULTI DOSE SAFETY, TOLERABILITY, PHARAMCOKINETICS, AND PHARACODYNAMICS STUDY OF SUBCUTANEOUSLY ADMINISTERED ALN-AS1 IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP)

1/22/16 → 1/21/19

Project: Other project

Porphyria Rare Disease Clinical Research Consortium (PDCRC)

9/27/14 → 8/31/19

Project: Other project

A Natural History Study of Acute Hepatic Porphyria (AHP) Patients with Recurrent Attacks ALN-AS1-NT-001

8/14/14 → 2/10/21

Project: Other project

A Natural History Study of Acute Hepatic Porphyria (AHP) Patients with Recurrent Attacks ALN-AS1-NT-001

8/14/14 → 2/10/21

Project: Other project

A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria

Recordati Rare Diseases Inc

11/12/13 → 8/31/21

Project: Other project

A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria

Recordati Rare Diseases Inc

11/12/13 → 8/31/21

Project: Other project

A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria